CCIA
BMRN icon

Campbell & Co Investment Adviser’s BioMarin Pharmaceuticals BMRN Stock Holding History

Campbell & Co Investment Adviser’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Buy
+23,603
New +$1.29M 0.07% 451
2026
Q1 		– Sell
-85,980
Closed -$5.11M – 1091
2025
Q4 		$5.11M Buy
85,980
+67,767
+372% +$3.69M 0.25% 90
2025
Q3 		$986K Sell
18,213
-56,336
-76% -$3.22M 0.07% 426
2025
Q2 		$4.1M Buy
+74,549
New +$4.39M 0.26% 68
2024
Q3 		– Sell
-13,186
Closed -$1.09M – 1099
2024
Q2 		$1.09M Sell
13,186
-18,924
-59% -$1.58M 0.09% 332
2024
Q1 		$2.8M Buy
32,110
+28,556
+803% +$2.56M 0.24% 73
2023
Q4 		$343K Buy
+3,554
New +$314K 0.03% 869
2023
Q3 		– Sell
-3,365
Closed -$292K – 954
2023
Q2 		$292K Buy
+3,365
New +$317K 0.05% 678
2023
Q1 		– Sell
-12,405
Closed -$1.28M – 815
2022
Q4 		$1.28M Buy
12,405
+7,955
+179% +$747K 0.31% 50
2022
Q3 		$377K Sell
4,450
-7,275
-62% -$648K 0.09% 404
2022
Q2 		$972K Buy
+11,725
New +$934K 0.26% 87
2022
Q1 		– Sell
-5,950
Closed -$526K – 702
2021
Q4 		$526K Buy
+5,950
New +$491K 0.18% 183
2019
Q2 		– Sell
-10,671
Closed -$948K – 537
2019
Q1 		$948K Buy
+10,671
New +$989K 0.47% 28
2017
Q3 		– Sell
-3,734
Closed -$339K – 357
2017
Q2 		$339K Buy
+3,734
New +$340K 0.32% 104
2017
Q1 		– Sell
-2,902
Closed -$240K – 154
2016
Q4 		$240K Buy
+2,902
New +$250K 0.74% 60
2015
Q4 		– Sell
-4,589
Closed -$483K – 93
2015
Q3 		$483K Buy
+4,589
New +$613K 0.32% 109
2014
Q2 		– Sell
-43,550
Closed -$2.97M – 163
2014
Q1 		$2.97M Buy
43,550
+33,953
+354% +$2.5M 1.2% 27
2013
Q4 		$675K Sell
9,597
-21,203
-69% -$1.44M 0.15% 148
2013
Q3 		$2.22M Sell
30,800
-67,236
-69% -$4.47M 0.44% 79
2013
Q2 		$5.46M Buy
+98,036
New +$6.11M 1.06% 23

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Campbell & Co Investment Adviser's BMRN Position: Q2 2026 in Review

Campbell & Co Investment Adviser opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 23,603 shares worth $1.35M. The stake represents 0.07% of the portfolio and ranks #451 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in BMRN as recently as Q4 2025.

Campbell & Co Investment Adviser first reported a position in BMRN in Q2 2013 and has held it in 20 quarters since. The position peaked at $5.46M in Q2 2013. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Campbell & Co Investment Adviser held 23,603 shares of BioMarin Pharmaceuticals worth $1.35M as of Q2 2026.
  • BioMarin Pharmaceuticals was a new Campbell & Co Investment Adviser position in Q2 2026.
  • BioMarin Pharmaceuticals made up 0.07% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #451 holding.
  • Campbell & Co Investment Adviser first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 20 quarters since.
  • Campbell & Co Investment Adviser's BioMarin Pharmaceuticals position peaked at $5.46M in Q2 2013.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.